Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 2/20 | 0.39 |
| ▸ | F9 | P00740 | 3/20 | 0.37 |
| ▸ | F10 | P00742 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.35 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131496 | 0.81 | HDAC1 (0.42) | CXCR4F9F10RORCTRPV1 | |
| SCHEMBL6131520 | 0.81 | CXCR4 (0.41) | CXCR4RORCCTNNB1TCF7L2TRPV1 | |
| SCHEMBL6131600 | 0.80 | CXCR4 (0.43) | CXCR4RORCCTNNB1TCF7L2BCHE | |
| SCHEMBL6131483 | 0.80 | CXCR4 (0.40) | CXCR4RORCCTNNB1TCF7L2 | |
| SCHEMBL6131482 | 0.78 | CXCR4 (0.43) | CXCR4BDKRB2ALDH1A1LMNA | |
| SCHEMBL6131474 | 0.77 | CXCR4 (0.40) | CXCR4RORCBDKRB2TRPV1 | |
| SCHEMBL6131506 | 0.77 | CXCR4 (0.43) | CXCR4RORCTRPV1 | |
| SCHEMBL12894415 | 0.77 | CXCR4 (0.55) | CXCR4RORCBDKRB2 | |
| SCHEMBL6131606 | 0.77 | CXCR4 (0.40) | CXCR4RORCCTNNB1TCF7L2BDKRB2 | |
| SCHEMBL5624699 | 0.77 | CXCR4 (0.42) | CXCR4RORCBDKRB2TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | claimed |
| US-20050165063-A1 | Amine compounds and use thereof | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED. (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1550657-A1 | AMINE COMPOUNDS AND USE THEREOF | Kureha Chemical Industry Co., Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165063-A1 | Amine compounds and use thereof | NR0B2, NR5A2, NR1H4 | CXCR4 90/4885F9 3872/4885F10 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.